Testsea expands global IVD reach with broad human and veterinary testing portfolio
Hangzhou Testsea Biotechnology says it supplies in vitro diagnostic products to more than 100 countries and regions, with products spanning infectious disease, reproductive health, cardiovascular and veterinary testing. The company is highlighting its research, manufacturing and international exhibition presence as global demand rises for faster and more accessible diagnostics.
Why it matters: - Demand for early disease detection, accessible testing and efficient clinical assessment is pushing growth in in vitro diagnostics. - Testsea is positioning its portfolio to serve both human healthcare and veterinary markets across multiple testing formats. - The company says its products are part of a broader shift toward point-of-care, molecular and combination testing.
What happened: - Hangzhou Testsea Biotechnology Co., Ltd. says it focuses on research, development, manufacturing and supply of in vitro diagnostic products for human healthcare and veterinary applications. - The company says its products have reached more than 100 countries and regions. - Testsea highlighted its portfolio in an announcement dated Nov. 17, 2026, from Hangzhou, Zhejiang, China. - The company directs readers to more information on its official website.
The details: - Testsea says its technology platforms cover immunological detection, molecular biology, protein-related testing and biological raw materials. - The company says it develops diagnostic solutions for infectious diseases, cardiovascular conditions, inflammation, reproductive health and other testing needs. - Founded in 2015, Hangzhou Testsea Biotechnology Co., Ltd. describes itself as a biomedical technology company focused on in vitro diagnostic and veterinary diagnostic products. - Testsea says it has research and production capabilities for diagnostic instruments, reagents and related materials used in POCT, biochemistry, immunology and molecular diagnosis. - Company materials report more than 50 authorized patents. - Testsea says its work on biological raw materials includes antibodies, antigens and other assay components that affect target recognition and analytical performance. - The company says it developed and launched SARS-CoV-2 detection products after the emergence of COVID-19, and related products later obtained regulatory approvals and certifications in several international markets.
Between the lines: - The pitch reflects how diagnostic makers are competing on breadth, speed and portability rather than single-test specialization. - Testsea is using international exhibitions and multi-category product coverage to appeal to distributors, labs and healthcare buyers in different regions. - The company’s mix of human and animal health products suggests a strategy to widen revenue opportunities and reduce reliance on any one market segment.
What's next: - Testsea says it will continue focusing on diagnostic technology research, product development and manufacturing across human and veterinary healthcare. - The company expects continued demand for POCT, molecular diagnostics, combination testing and biomarker detection. - Testsea says it will keep expanding international business development and cooperation with distributors and healthcare professionals.
The bottom line: - Testsea is marketing itself as a broad-based IVD supplier built for global distribution, faster testing and multiple clinical use cases.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Thailand Health Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.